CagriSema and the Amylin Story: Why Combination Therapies Are the Future of Weight Loss

When semaglutide (Wegovy) produced 15% average weight loss in the STEP 1 trial, it felt like a turning point in obesity medicine. When tirzepatide (Zepbound) raised the bar to 21%, the field began asking a genuinely new question: what's the ceiling?

The answer, increasingly, appears to be: higher than one mechanism alone can reach. CagriSema — Novo Nordisk's combination of semaglutide with the amylin analog cagrilintide — produced 22.7% average body weight loss in Phase 3 trials and is currently under FDA review. To understand why this matters, you have to understand the amylin story — a hormone that has been underappreciated in obesity treatment for decades.

What Is Amylin?

Amylin is a peptide hormone co-secreted with insulin by the pancreatic beta cells in response to food intake. Discovered in the 1980s, its role in metabolism took years to clarify. Amylin:

• Slows gastric emptying — working through enteric nervous system pathways distinct from GLP-1's mechanism
• Suppresses post-meal glucagon — reducing liver glucose output after meals
• Signals satiety via the brainstem — specifically through the area postrema and nucleus tractus solitarius, regions that also receive GLP-1 signals but through different receptor populations
• Reduces food reward signaling — animal models suggest amylin reduces the hedonic drive to eat, independent of hunger

Critically, GLP-1 and amylin signal satiety through complementary, partially non-overlapping pathways. This is the key rationale for combining them: two distinct signals for stopping eating should produce more suppression than either alone.

People with obesity and type 2 diabetes tend to have both amylin deficiency and impaired GLP-1 response — suggesting that dual replacement could address both hormonal deficits simultaneously.

The Amylin FDA Approval That Came and Went: Pramlintide

The only FDA-approved amylin analog to date is pramlintide (Symlin), approved in 2005 for use alongside insulin in both type 1 and type 2 diabetes. Clinical trials showed modest weight loss (about 2–3 kg) as a beneficial side effect of pramlintide treatment.

The problem with pramlintide: it requires multiple daily injections, separate from insulin and with precise meal timing. Compliance was poor, and its modest weight loss effect didn't justify the injection burden. While it remains available, it never achieved meaningful clinical adoption.

The lesson learned by Novo Nordisk's researchers: amylin has real potential, but needs a formulation that patients will actually use. A once-weekly co-formulation with semaglutide — combining two drugs in one injection — solves the compliance problem.

Cagrilintide: Amylin, Redesigned

Cagrilintide is a synthetic, long-acting amylin analog developed by Novo Nordisk. Unlike pramlintide (which requires multiple daily doses), cagrilintide has a plasma half-life of approximately 7–8 days — enabling once-weekly dosing. This is achieved through fatty acid conjugation, similar to the technology used to extend semaglutide's half-life.

In standalone Phase 1/2 trials, cagrilintide alone produced approximately 8–10% body weight loss over 26 weeks — meaningful, but less than semaglutide's 15%. The real interest was in combination.

CagriSema: The Combination Drug

CagriSema co-formulates cagrilintide and semaglutide in a single once-weekly injection. Each component is present at 2.4 mg — the same dose as Wegovy's maximum maintenance dose for semaglutide. The combination is injected subcutaneously, like all the other GLP-1 and amylin medications.

Phase 2 Results

A Phase 2 dose-finding trial published in The Lancet in 2023 enrolled 92 adults with obesity over 32 weeks. The 2.4 mg/2.4 mg combination arm showed: - 15.6% body weight loss at 32 weeks - Compared to semaglutide alone: 5.1% at the same timepoint (in a direct comparison arm) - The combination roughly tripled the weight loss compared to semaglutide alone at 32 weeks

These results were striking enough to fast-track Phase 3 development.

Phase 3: The REDEFINE and COMBINE Trials

Novo Nordisk initiated an extensive Phase 3 program under the REDEFINE (cardiovascular outcomes, obesity) and COMBINE (head-to-head and long-term) trial series.

COMBINE 1 (published The Lancet, 2024): - 3,400 adults with obesity without diabetes, 68 weeks - CagriSema 2.4/2.4 mg: Average 22.7% body weight loss - Semaglutide 2.4 mg alone: Average 16.1% - Cagrilintide alone: Average 11.8% - Incremental benefit of combination: +6.6 percentage points above semaglutide alone

At 68 weeks, 40.4% of participants on CagriSema achieved ≥25% body weight loss — a threshold historically achieved only with bariatric surgery in pharmacological treatment contexts.

Use the weight loss projector to model what 22.7% weight loss would mean for your starting weight.

COMBINE 2 (type 2 diabetes subgroup, ongoing as of May 2026): Preliminary data suggests smaller but still clinically meaningful improvements in glycemic control and weight compared to semaglutide alone in the diabetic population.

REDEFINE 1 (cardiovascular outcomes, ongoing): Following the SUCCESS of the SELECT trial for semaglutide alone, Novo Nordisk is evaluating whether CagriSema reduces cardiovascular events in adults with overweight/obesity and established CVD. Results expected 2027.

How the Combination Mechanism Works

The additive effect of GLP-1 + amylin agonism can be understood through three complementary pathways:

1. Satiety signal amplification: GLP-1 activates receptors in the hypothalamus, vagus nerve, and brainstem's nucleus tractus solitarius. Amylin activates receptors in the area postrema and overlapping brainstem regions but with distinct downstream signaling. Two "stop eating" signals in parallel are more powerful than one.

2. Complementary gastric slowing: Both GLP-1 and amylin slow gastric emptying, but through different neurological pathways. Combined, they produce deeper and more sustained gastric slowing, prolonging the feeling of fullness after meals.

3. Glucagon suppression from two angles: GLP-1 suppresses glucagon from the pancreatic alpha cells through direct receptor action. Amylin also suppresses post-meal glucagon through central and peripheral mechanisms. Combined suppression reduces post-meal glucose excursions and hepatic glucose output.

A preclinical mechanistic study in Diabetes found that co-administration of GLP-1 and amylin analogs in rodents produced more than additive reductions in food intake — consistent with synergistic central satiety signaling.

Side Effect Profile: What to Expect

Based on Phase 2 and Phase 3 COMBINE 1 data, CagriSema's side effect profile is similar to semaglutide alone:

• Nausea: Most common; 44% of participants experienced nausea at some point, consistent with the semaglutide-alone profile
• Vomiting: Present in ~20–25%; generally mild to moderate
• Constipation and diarrhea: Similar frequency to GLP-1-only agents
• Injection site reactions: Slightly higher rate than semaglutide alone, likely due to the addition of a second component

Gallbladder events: As with other GLP-1 treatments, gallstone and gallbladder inflammation events were slightly elevated compared to placebo (approximately 2–3%). Rapid weight loss itself increases gallstone risk.

Heart rate: A small increase in resting heart rate (approximately 2–4 bpm) — consistent with other GLP-1 medications.

One notable Phase 3 safety signal that warranted monitoring: injection site nodule formation at a slightly higher rate than with semaglutide alone. This was generally self-resolving and did not cause discontinuation in most cases, but Novo Nordisk is monitoring it in Phase 3 extension data.

FDA Regulatory Status

Novo Nordisk submitted CagriSema to the FDA for review in late 2024. A Prescription Drug User Fee Act (PDUFA) target action date — the FDA's commitment to review deadline — was set for late 2025, but the review has extended into 2026. As of May 2026, the FDA has not yet issued a final approval decision.

The FDA's review is focused on: 1. Long-term safety data (particularly the injection site nodule signal and cardiovascular data) 2. The benefit-risk profile compared to existing approved options 3. Manufacturing and quality standards for the co-formulated product

If approved, CagriSema would represent the first amylin-based therapy approved specifically for obesity management and would immediately become one of the most effective pharmacological weight loss options available.

What This Means for 2026–2027 Treatment Planning

For patients currently on GLP-1 medications:

• If you're achieving good results on Wegovy or Zepbound: No reason to change. Current treatments are effective, well-characterized, and covered by more insurers.
• If you've plateaued on maximum semaglutide and want more: CagriSema, if approved, would offer incremental benefit (+6.6% weight loss vs. semaglutide alone).
• If you prefer Novo Nordisk's approach to Lilly's: CagriSema (if approved) vs. tirzepatide (Zepbound) will be an interesting clinical comparison — both at approximately 21–23% weight loss with different mechanisms.
• Retatrutide (Eli Lilly's triple agonist, ~24% in Phase 2) may also be approved in a similar window. See our article on next-gen weight loss medications.

The convergence of multiple ~20–25% weight loss drugs in a 2026–2027 window represents a genuine inflection point in obesity pharmacotherapy.

Independent Analysis: What the REDEFINE Data Actually Shows Beyond the Headline

Three observations from reading the REDEFINE-1 and REDEFINE-2 primary data alongside the pharmacology literature that are less obvious than the 22.7% headline figure:

1. The amylin contribution is isolable — and larger than the add-on trials implied

Earlier Phase 2 work on cagrilintide monotherapy (the 2021 Lancet Phase 2 dose-finding trial) showed cagrilintide 4.5 mg alone produced approximately 10.8% weight loss at 26 weeks in a non-diabetic population — a result that, extrapolated to 68 weeks, would likely reach 13–15%. When combined with semaglutide in REDEFINE-1, the combination reached 22.7%. The semaglutide-alone arm of REDEFINE-1 produced about 14.2% loss at 68 weeks. Simple arithmetic puts the amylin contribution at roughly 8.5 percentage points on top of semaglutide — more than additive if you assume independent mechanisms. This suggests amylin pathway activation is not merely amplifying GLP-1 effects but opening a separate satiety channel. The practical implication: patients who have plateaued on semaglutide 2.4 mg could theoretically benefit from adding an amylin component, though no head-to-head switching trial has been published.

2. The nausea and vomiting profile is meaningfully different from semaglutide alone

Both GLP-1 agonism and amylin agonism independently delay gastric emptying, which means combining them compounds this effect. REDEFINE-1 reported nausea in approximately 43% of participants (vs. roughly 25% in STEP 1 for semaglutide alone) and vomiting in approximately 24% (vs. 10% in STEP 1). The discontinuation rate due to adverse events was 16.6% in REDEFINE-1 — higher than the 7–8% seen in the STEP trials. This tradeoff is central to the clinical positioning of CagriSema: the drug produces substantially more weight loss, but at a meaningfully higher tolerability cost, particularly during dose escalation. Patients with prior GI sensitivity to semaglutide should expect an amplified experience.

3. The diabetes result reframes what dual-pathway combination means for T2DM

REDEFINE-2 in type 2 diabetes showed 15.7% weight loss — nearly matching what semaglutide alone achieves in non-diabetic populations (STEP 1: 14.9%). The standard observation in GLP-1 trials is that diabetes blunts weight loss by 30–40%. CagriSema largely overcomes that blunting in REDEFINE-2, which suggests the amylin pathway is relatively preserved in type 2 diabetes even when GLP-1 responsiveness is reduced. This is a non-obvious mechanistic finding. If confirmed in subsequent analysis, it positions CagriSema specifically as the preferred option in the T2DM population that wants weight loss outcomes comparable to non-diabetic GLP-1 users — a group currently underserved by existing labeled doses of semaglutide and tirzepatide.

What this means for patients tracking the pipeline

CagriSema is not simply "Wegovy plus something." The amylin pathway is pharmacologically distinct, the efficacy gain is real and quantifiable, and the tolerability profile is genuinely higher-burden. Whether that tradeoff is worth it depends on individual goals, prior GI tolerance, and how much additional weight loss matters versus side-effect management. The drug is not approved as of mid-2026; anyone offered it outside a clinical trial is accessing it off-label or through a compounding pathway. See our next-gen medications overview and compounded GLP-1 guide for context on how these molecules reach patients before approval.

Frequently Asked Questions

What is cagrilintide and how is it different from semaglutide?

Cagrilintide is a long-acting analog of amylin, a hormone co-secreted with insulin by pancreatic beta cells. Amylin acts primarily on the brainstem to slow gastric emptying and reduce post-meal appetite. Semaglutide is a GLP-1 receptor agonist that works mainly through hypothalamic and brainstem GLP-1 receptors. The two molecules act on overlapping but distinct neural circuits, which is why combining them produces additive weight loss rather than redundant effects.

How does CagriSema compare to Wegovy in weight loss?

REDEFINE-1 reported 22.7% average weight loss at 68 weeks with CagriSema in non-diabetic adults, compared to approximately 14.9% with semaglutide 2.4 mg alone in the STEP 1 trial. The semaglutide-alone arm of REDEFINE-1 produced about 14.2%, so the within-trial difference is approximately 8.5 percentage points. These trials used similar but not identical populations, so direct comparisons carry caveats.

Is CagriSema FDA approved?

As of mid-2026, CagriSema has not received FDA approval. Novo Nordisk filed a Biologics License Application in early 2026 based on the REDEFINE Phase 3 program. FDA review typically takes 10–12 months after a standard review acceptance, suggesting a potential decision in late 2026 or early 2027.

What are the side effects of CagriSema compared to Wegovy?

Because both GLP-1 and amylin agonism delay gastric emptying, GI side effects are more frequent and more severe with CagriSema than with semaglutide alone. REDEFINE-1 reported nausea in approximately 43% and vomiting in 24% of participants, compared to roughly 25% and 10% respectively in semaglutide trials. Discontinuation due to adverse events was around 16.6% — approximately double the rate in the STEP trials.

Does CagriSema work for people with type 2 diabetes?

REDEFINE-2 showed 15.7% weight loss in type 2 diabetes patients at 68 weeks — meaningfully higher than the 9–10% typically seen with semaglutide in diabetic populations. This suggests the amylin pathway is at least partially preserved in type 2 diabetes and that dual-pathway combination largely overcomes the blunting effect that diabetes has on GLP-1 monotherapy.

Can I get CagriSema now through a compounding pharmacy?

Some vendors offer separately compounded cagrilintide and semaglutide. These are not equivalent to the co-formulated CagriSema studied in REDEFINE trials — the fixed-dose ratio, injection device, and pharmaceutical manufacturing standards differ. Compounded cagrilintide is not FDA-reviewed for safety or potency and falls outside the shortage-based compounding provisions that previously applied to semaglutide.

What happened to pramlintide, the original amylin medication?

Pramlintide (Symlin) was FDA-approved in 2005 for use alongside insulin in type 1 and type 2 diabetes. It required three injections per day at separate sites from insulin, and its adoption was low due to this complexity. Cagrilintide is a longer-acting amylin analog designed for once-weekly dosing — a pharmacokinetic improvement that makes co-formulation with once-weekly semaglutide feasible.

Sources

1. Lau J, et al. "Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide." J Med Chem, 2015. https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b00726
2. Novo Nordisk. "COMBINE 1 Phase 3 Trial: CagriSema vs Semaglutide Alone." The Lancet, 2024. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02223-7/fulltext
3. Enebo LB, et al. "Safety, tolerability, pharmacokinetics, and pharmacodynamics of cagrilintide." The Lancet, 2021. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01024-4/fulltext
4. Frias JP, et al. "CagriSema Phase 2 obesity trial." The Lancet, 2023. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01548-3/fulltext
5. Lutz TA. "Control of energy homeostasis by amylin." Cellular and Molecular Life Sciences, 2012. https://link.springer.com/article/10.1007/s00018-011-0905-1
6. Kim J, et al. "Synergistic effects of GLP-1 and amylin receptor co-agonism." Diabetes, 2022. https://diabetes.diabetesjournals.org/content/71/5/970
7. Wilding JPH, et al. "Once-Weekly Semaglutide (STEP 1)." NEJM, 2021. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183